Author:
Zheng Jia,Zhang Wei,Li Linfeng,He Yi,Wei Yue,Dang Yongjun,Nie Shenyou,Guo Zufeng
Abstract
Targeted therapy is a groundbreaking innovation for cancer treatment. Among the receptor tyrosine kinases, the fibroblast growth factor receptors (FGFRs) garnered substantial attention as promising therapeutic targets due to their fundamental biological functions and frequently observed abnormality in tumors. In the past 2 decades, several generations of FGFR kinase inhibitors have been developed. This review starts by introducing the biological basis of FGF/FGFR signaling. It then gives a detailed description of different types of small-molecule FGFR inhibitors according to modes of action, followed by a systematic overview of small-molecule-based therapies of different modalities. It ends with our perspectives for the development of novel FGFR inhibitors.
Reference206 articles.
1. Advances in Covalent Kinase Inhibitors;Abdeldayem;Chem. Soc. Rev.,2020
2. A Highly Potent TACC3 Inhibitor as a Novel Anticancer Drug Candidate;Akbulut;Mol. Cancer Ther.,2020
3. Circulating Fibroblast Growth Factors as Metabolic Regulators-A Critical Appraisal;Angelin;Cel Metab.,2012
4. Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma;Angevin;Clin. Cancer Res.,2013
5. Small Molecule Kinase Inhibitor Drugs (1995-2021): Medical Indication, Pharmacology, and Synthesis;Ayala-Aguilera;J. Med. Chem.,2022
Cited by
41 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献